AquaBounty Technologies (NASDAQ:AQB) vs. Yarrow Bioscience (NASDAQ:YARW) Head-To-Head Analysis

Yarrow Bioscience (NASDAQ:YARW) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Volatility and Risk

Yarrow Bioscience has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.

Earnings and Valuation

This table compares Yarrow Bioscience and AquaBounty Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570,000.00	137.20	-$26.48 million	($14.64)	-2.00
AquaBounty Technologies	$2.47 million	2.38	-$18.49 million	($0.82)	-1.39

AquaBounty Technologies has higher revenue and earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Yarrow Bioscience and AquaBounty Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Insider and Institutional Ownership

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Yarrow Bioscience and AquaBounty Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1	0	2	0	2.33
AquaBounty Technologies	1	0	0	0	1.00

Yarrow Bioscience currently has a consensus price target of $58.00, indicating a potential upside of 98.02%. Given Yarrow Bioscience’s stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than AquaBounty Technologies.

Summary

Yarrow Bioscience beats AquaBounty Technologies on 8 of the 14 factors compared between the two stocks.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About AquaBounty Technologies

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.